Understanding ADTKD-SEC61A1 (ADTKD-6)

Receiving a diagnosis of ADTKD-SEC61A1 can feel overwhelming, especially because it is one of the rarest forms of kidney disease in the world. You may see this condition referred to as ADTKD-6 in some older or informal contexts, but current medical standards (called the KDIGO consensus guidelines) recommend naming it after the specific gene involved ^[1][2]. This gene-based naming helps doctors more accurately track and understand the biological cause.

An Ultra-Rare Journey

You are part of an extremely small global community. As of recent reviews, current medical literature has only documented a small number of published cases—approximately 15 to 20 individuals—worldwide ^[3]. Because so few people have been diagnosed, doctors are still learning about the full range of symptoms, which can vary significantly even between members of the same family ^[3][4].

The “Cellular Doorway”: Experimental Mechanisms

To understand this condition, it helps to think of cells as tiny factories. Inside each cell is a structure called the endoplasmic reticulum (ER), which acts as the main production floor for making proteins ^[2].

The SEC61A1 gene provides instructions for building a “pore” or a doorway in the ER wall. This doorway is called the translocon. Experimental laboratory studies suggest its job is twofold:

1. Protein Transport: It allows newly made proteins to enter the ER so they can be folded and processed before being shipped to the rest of the body ^[2].
2. Calcium Balance: It helps regulate the flow of calcium ions, which are critical signals the cell uses to stay healthy and function correctly ^[2].

In laboratory models of ADTKD-SEC61A1, these doorways do not function properly. Research shows that specific mutations can alter calcium regulation and selectively block the transport of renin, a vital hormone produced by the kidneys that helps control blood pressure ^[2]. It is important to note that these are proposed disease mechanisms based on experimental models, and they may differ depending on the exact genetic variant a person carries.

Beyond the Kidneys

Because the SEC61A1 gene is active in many parts of the body, this condition can sometimes affect more than just the kidneys. While the primary concern is often the gradual decline in kidney function (characterized by a “bland” urine profile), other reported features in the limited case literature include:

• Blood-Related Issues: Some individuals experience anemia (low red blood cells) or neutropenia (low white blood cells), which may be noticed early in life ^[5][3].
• Growth and Development: There have been reports of intrauterine growth restriction (smaller size at birth), failure to thrive in infancy, or general growth delays later in childhood ^[3][6].
• Hormonal Balance: Some specific reported cases have included very low levels of aldosterone (another blood-pressure hormone) and low renin, leading to low blood pressure and salt imbalances ^[6]. Note that these hormone abnormalities can also have other causes and are not automatically expected in every patient.
• Neurological Findings: In very rare, isolated instances, seizures, microcephaly (smaller head size), or developmental delays have been observed ^[7][3].

What is Known vs. What is Uncertain

We know that mutations in the SEC61A1 gene cause progressive kidney disease and can be inherited. However, because of the small number of reported cases, the exact frequency of extra-renal symptoms, the precise timeline of progression, and how individual variants behave remain uncertain. Knowing the specific gene involved allows your medical team to move beyond general kidney care and proactively monitor for the specific blood, growth, and hormonal issues that have been associated with SEC61A1 ^[6][3].